CEACAM5 and gastric cancer: Herein, the eligible patients given S-1 therapy plus apatinib showed significantly lower levels of serum CEA, CA199, and CA125 versus those receiving S-1 therapy, suggesting that apatinib plus S-1 therapy can significantly reduce tumor marker expression in patients with advanced gastric cancer.